181 related articles for article (PubMed ID: 18611063)
1. A model of the kinetics of lanthanum in human bone, using data collected during the clinical development of the phosphate binder lanthanum carbonate.
Bronner F; Slepchenko BM; Pennick M; Damment SJ
Clin Pharmacokinet; 2008; 47(8):543-52. PubMed ID: 18611063
[TBL] [Abstract][Full Text] [Related]
2. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?
Behets GJ; Dams G; Vercauteren SR; Damment SJ; Bouillon R; De Broe ME; D'Haese PC
J Am Soc Nephrol; 2004 Aug; 15(8):2219-28. PubMed ID: 15284308
[TBL] [Abstract][Full Text] [Related]
3. Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate.
Behets GJ; Verberckmoes SC; Oste L; Bervoets AR; Salomé M; Cox AG; Denton J; De Broe ME; D'Haese PC
Kidney Int; 2005 May; 67(5):1830-6. PubMed ID: 15840030
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate.
Damment SJ; Pennick M
Clin Pharmacokinet; 2008; 47(9):553-63. PubMed ID: 18698878
[TBL] [Abstract][Full Text] [Related]
5. Lanthanum carbonate: a new phosphate binder.
Behets GJ; Verberckmoes SC; D'Haese PC; De Broe ME
Curr Opin Nephrol Hypertens; 2004 Jul; 13(4):403-9. PubMed ID: 15199290
[TBL] [Abstract][Full Text] [Related]
6. Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate.
Pennick M; Dennis K; Damment SJ
J Clin Pharmacol; 2006 Jul; 46(7):738-46. PubMed ID: 16809799
[TBL] [Abstract][Full Text] [Related]
7. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up.
Spasovski GB; Sikole A; Gelev S; Masin-Spasovska J; Freemont T; Webster I; Gill M; Jones C; De Broe ME; D'Haese PC
Nephrol Dial Transplant; 2006 Aug; 21(8):2217-24. PubMed ID: 16595583
[TBL] [Abstract][Full Text] [Related]
8. Dietary administration in rodent studies distorts the tissue deposition profile of lanthanum carbonate; brain deposition is a contamination artefact?
Damment SJ; Cox AG; Secker R
Toxicol Lett; 2009 Aug; 188(3):223-9. PubMed ID: 19464128
[TBL] [Abstract][Full Text] [Related]
9. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.
D'Haese PC; Spasovski GB; Sikole A; Hutchison A; Freemont TJ; Sulkova S; Swanepoel C; Pejanovic S; Djukanovic L; Balducci A; Coen G; Sulowicz W; Ferreira A; Torres A; Curic S; Popovic M; Dimkovic N; De Broe ME
Kidney Int Suppl; 2003 Jun; (85):S73-8. PubMed ID: 12753271
[TBL] [Abstract][Full Text] [Related]
10. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study.
Al-Baaj F; Speake M; Hutchison AJ
Nephrol Dial Transplant; 2005 Apr; 20(4):775-82. PubMed ID: 15703206
[TBL] [Abstract][Full Text] [Related]
11. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
Finn WF; Joy MS;
Curr Med Res Opin; 2005 May; 21(5):657-64. PubMed ID: 15969865
[TBL] [Abstract][Full Text] [Related]
12. Lanthanum carbonate.
Freemont AJ
Drugs Today (Barc); 2006 Dec; 42(12):759-70. PubMed ID: 17285149
[TBL] [Abstract][Full Text] [Related]
13. Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients.
Albaaj F; Hutchison AJ
Int J Clin Pract; 2005 Sep; 59(9):1091-6. PubMed ID: 16115187
[TBL] [Abstract][Full Text] [Related]
14. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration.
Lacour B; Lucas A; Auchère D; Ruellan N; de Serre Patey NM; Drüeke TB
Kidney Int; 2005 Mar; 67(3):1062-9. PubMed ID: 15698446
[TBL] [Abstract][Full Text] [Related]
15. Systemic lanthanum is excreted in the bile of rats.
Damment SJ; Pennick M
Toxicol Lett; 2007 Jun; 171(1-2):69-77. PubMed ID: 17570622
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
Joy MS; Finn WF;
Am J Kidney Dis; 2003 Jul; 42(1):96-107. PubMed ID: 12830461
[TBL] [Abstract][Full Text] [Related]
17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
18. Restoration of parathyroid function after change of phosphate binder from calcium carbonate to lanthanum carbonate in hemodialysis patients with suppressed serum parathyroid hormone.
Inaba M; Okuno S; Nagayama H; Yamada S; Ishimura E; Imanishi Y; Shoji S
J Ren Nutr; 2015 Mar; 25(2):242-6. PubMed ID: 25556148
[TBL] [Abstract][Full Text] [Related]
19. Lanthanum carbonate.
Swainston Harrison T; Scott LJ
Drugs; 2004; 64(9):985-96; discussion 997-8. PubMed ID: 15101790
[TBL] [Abstract][Full Text] [Related]
20. Improving phosphate-binder therapy as a way forward.
Hutchison AJ
Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i19-24. PubMed ID: 15126650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
